B. Riley Has Positive Estimate for KRMD FY2024 Earnings

KORU Medical Systems, Inc. (NASDAQ:KRMD - Free Report) - Analysts at B. Riley lifted their FY2024 earnings estimates for KORU Medical Systems in a research report issued to clients and investors on Tuesday, January 14th. B. Riley analyst K. Bauser now expects that the company will earn ($0.13) per share for the year, up from their previous estimate of ($0.14). The consensus estimate for KORU Medical Systems' current full-year earnings is ($0.14) per share. B. Riley also issued estimates for KORU Medical Systems' Q4 2024 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.09) EPS.

Several other analysts also recently commented on KRMD. Piper Sandler increased their price objective on KORU Medical Systems from $3.00 to $3.50 and gave the stock an "overweight" rating in a research note on Thursday, November 14th. Craig Hallum raised their price objective on KORU Medical Systems from $4.00 to $5.00 and gave the company a "buy" rating in a research note on Thursday, November 14th. Lake Street Capital upped their target price on shares of KORU Medical Systems from $4.00 to $5.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, Canaccord Genuity Group increased their target price on shares of KORU Medical Systems from $3.00 to $4.00 and gave the company a "buy" rating in a report on Thursday, November 14th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $4.30.

KORU Medical Systems Stock Up 1.5 %

Shares of KRMD traded up $0.06 on Thursday, reaching $4.00. The company's stock had a trading volume of 27,843 shares, compared to its average volume of 99,424. The stock has a market capitalization of $183.36 million, a PE ratio of -16.00 and a beta of 0.45. The company has a current ratio of 2.99, a quick ratio of 2.37 and a debt-to-equity ratio of 0.01. KORU Medical Systems has a twelve month low of $1.98 and a twelve month high of $4.60. The firm has a fifty day moving average of $3.77 and a 200-day moving average of $2.95.

Institutional Investors Weigh In On KORU Medical Systems

Hedge funds have recently made changes to their positions in the business. Meros Investment Management LP grew its position in KORU Medical Systems by 20.7% during the second quarter. Meros Investment Management LP now owns 804,380 shares of the company's stock valued at $2,132,000 after buying an additional 137,918 shares during the period. Geode Capital Management LLC boosted its stake in KORU Medical Systems by 6.5% in the third quarter. Geode Capital Management LLC now owns 462,128 shares of the company's stock valued at $1,262,000 after acquiring an additional 28,323 shares during the last quarter. Empire Financial Management Company LLC bought a new position in shares of KORU Medical Systems during the 3rd quarter valued at approximately $259,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of KORU Medical Systems by 77.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 61,412 shares of the company's stock worth $168,000 after purchasing an additional 26,860 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of KORU Medical Systems in the 2nd quarter worth approximately $107,000. 58.60% of the stock is currently owned by institutional investors.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.